NephroGenex, a Triangle-based drug developer that went public in 2014 for some $37 million but whose stock has fallen to the point of being delisted, has ousted its CEO and chief science officer.
NephroGenex (Nasdaq: NRX) is seeking to develop a treatment for diabetic nephropathy.
Shares closed at 40 cents on Thursday. They had at one time listed for
Chief Financial Officer John Hamill takes over as CEO.
Leaving the company but still serving as consultants are Pierre Legault, who was CEO, and Jaikrishna Patel, the CSO.
In February, the company stopped clinical research program for nephropathy – and much more. It said it would consider a “strategic transaction” that turned out to be a reverse merger.
NephroGenex disclosed the executive changes in a securities filing on Wednesday.
See more at:
https://biz.yahoo.com/e/160413/nrx8-k.html
